title: Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.
abstract: OBJECTIVE
  We studied the link between T-cell activation, differentiation and senescence phenotypes and non-AIDS-related comorbidities in HIV-suppressed patients.
  
  
  METHODS
  Patients included in the ANRS CO3 Aquitaine Cohort were consecutively enrolled in this cross-sectional study between October 2011 and May 2013 called Chronic Immune Activation and Senescence (CIADIS) study.
  
  
  METHODS
  We summarized immune markers [CD4 and CD8 activation (DR), differentiation (naive and terminally differentiated memory T cells), and senescence (CD57CD28)] in a weighted immune score by principal component analysis called CIADIS. Previously described Veterans Aging Cohort Study (VACS) index and immune risk profile (IRP) scores were calculated. We used adjusted logistic regression to assess the association between the CIADIS score and the presence of at least three non-AIDS-defining comorbidities.
  
  
  RESULTS
  Of 876 patients with an undetectable viral load, 73.4% were men and median age was 50.5 years [interquartile range (IQR) 44.7-56.7 years]. Median CD4 T-cell count was 579/μl (IQR 429-759 cells/μl), and median duration of HIV viral suppression was 5.3 years (IQR 2.3-8.7). The weighted CIADIS score was associated with at least three comorbidities (odds ratio 1.3 for 1 SD more, 95% confidence interval 1.0, 1.6) independently of age, sex, AIDS stage, and the Veterans Aging Cohort Study score. The CIADIS and the immune risk profile scores were significantly associated with at least three comorbidities in adjusted models restricted to patients younger than 60 years. None of the tested scores were associated with at least three comorbidities in patients older than 60 years.
  
  
  CONCLUSIONS
  The weighted CIADIS score based on activation, senescence, and differentiation markers might help physicians identifying patients at a higher risk for non-AIDS-related comorbidities.
authors.affiliation: aCHU de Bordeaux, Service de médecine interne et immunologie clinique Bordeaux bUniversity Bordeaux, CIRID cCNRS, CIRID, UMR 5164 dUniversity Bordeaux, ISPED eINSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique fCHU de Bordeaux, Pôle de santé publique, Service d'information médicale gCHU de Bordeaux, Service de Médecine interne et maladies infectieuses hCHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, University Bordeaux iCHU de Bordeaux, Service de Maladies Infectieuses et Tropicales jINRIA, Equipe SISTM, Bordeaux, France. †Pierre Duffau and Linda Wittkop contributed equally to the writing of this article.
authors.forename: Pierre
authors.initials: P
authors.lastname: Duffau
authors.forename: Linda
authors.initials: L
authors.lastname: Wittkop
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Lazaro
authors.forename: Fabien
authors.initials: F
authors.lastname: le Marec
authors.forename: Céline
authors.initials: C
authors.lastname: Cognet
authors.forename: Patrick
authors.initials: P
authors.lastname: Blanco
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Moreau
authors.forename: Frédéric-Antoine
authors.initials: FA
authors.lastname: Dauchy
authors.forename: Charles
authors.initials: C
authors.lastname: Cazanave
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Vandenhende
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bonnet
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Thiebaut
authors.forename: Isabelle
authors.initials: I
authors.lastname: Pellegrin
mesh_terms: D000328:Adult; D002454:Cell Differentiation; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*